GLP-1 drugs target brain cells previously linked to hunger to boost fat burning

The brain cell considered an obstacle to weight loss may, in fact, be essential for maintaining this process. This discovery, released on September 1, 2026, suggests a new path to more effective treatments.
Researchers at Yale University investigated the mechanism of action of GLP-1 drugs in the brain, focusing on how its main component, semaglutide, contributes to sustaining weight loss. The findings were published in the Proceedings of the National Academy of Sciences in July.
The team discovered that the AgRP (agouti-related peptide) neuron, known to stimulate hunger, is intensely activated by semaglutide. However, instead of increasing appetite, this activation caused the body to burn more fat at rest.
Studies with mice that were genetically modified to lack AgRP neurons showed that these animals lost less weight and were unable to maintain the long-term reduction with GLP-1s. In contrast, mice without genetic alterations lost weight and maintained a reduction of about 10% to 15%.
Although it is not feasible to test AgRP neurons in living humans today, those behind the research hope that the data collected will guide other scientists in developing new approaches to treating obesity.
“By identifying a previously unknown neural mechanism involved in maintaining weight loss, our work offers new biological insights that could eventually help researchers develop even more effective therapies or therapies with fewer side effects,” said study author Mateus d’Ávila.






